Drug intelligence / Profile preview

RBM-011

Development stage: Preclinical
Lead developer: Ribomic
Modality: RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

RBM-011 is an aptamer therapeutic developed by Ribomic Inc. that targets interleukin-21 (IL-21). It is designed to treat pulmonary arterial hypertension (PAH) by blocking the activity of IL-21, a cytokine that promotes the proliferation of pulmonary artery smooth muscle cells. Unlike existing PAH therapies that primarily focus on vasodilation, RBM-011 aims to address the underlying pathology of the disease by suppressing arterial hyperplasia and stenosis. The drug was discovered using Ribomic's proprietary RiboART system platform and is currently in the preclinical development stage.

Other names: IL-21 inhibitory aptamerIL21 inhibitory aptamerIL 21 inhibitory aptamer

Targets

IL21 (Interleukin-21)

Beyond the preview

Go deeper on RBM-011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RBM-011.

Explore the full profile